Application of the '5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE.

Autor: Aldred J; Selkirk Neurology & Inland Northwest Research, Spokane, 610 S Sherman St #201 & 208, Spokane, WA 99202, USA., Anca-Herschkovitsch M; Department of Neurology, Edith Wolfson Medical Center Affiliated to Tel Aviv University, 62 Ha-Lokhamim St, Holon, Israel., Antonini A; Department of Neuroscience, Padua University, 5 - 35128 Padova, Padua, Veneto, Italy., Bajenaru O; Department of Neurology, University of Medicine & Pharmacy 'Carol Davila', Bulevardul Eroii Sanitari 8, Bucharest, Romania., Bergmann L; AbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USA., Bourgeois P; Department of Neurology AZ Groeninge, President Kennedylaan 4, Kortrijk, Belgium., Cubo E; Neurology Department, Hospital Universitario Burgos, Av. Islas Baleares, 3, Burgos, Spain., Davis TL; Department of Neurology, Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville, TN 37232, USA., Iansek R; Kingston Centre, Monash Health, 400 Warrigal Rd, Melbourne, Victoria, Australia., Kovács N; Department of Neurology, University of Pecs, 48-as tér 1, Pecs, Hungary., Kukreja P; AbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USA., Onuk K; AbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USA., Pontieri FE; Department of Neurological Sciences, Sapienza University of Rome, Piazzale Aldo Moro, 5, Rome, Italy., Robieson W; AbbVie, Inc., 1 Waukegan Rd, North Chicago, IL 60064, USA., Siddiqui MS; Department of Neurology, Wake Forest School of Medicine, 475 Vine St, Winston Salem, NC 27101, USA., Simu M; Department of Neurology, Victor Babes University of Medicine & Pharmacy, Piaţa Eftimie Murgu 2, Timisoara, Romania., Standaert DG; Department of Neurology, University of Alabama at Birmingham, 1720 University Blvd, Birmingham, AL 35294, USA., Chaudhuri KR; Parkinson Foundation International Centre of Excellence, King's College & King's College Hospital, Denmark Hill, London, UK.
Jazyk: angličtina
Zdroj: Neurodegenerative disease management [Neurodegener Dis Manag] 2020 Oct; Vol. 10 (5), pp. 309-323. Date of Electronic Publication: 2020 Sep 02.
DOI: 10.2217/nmt-2020-0021
Abstrakt: Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the '5-2-1 criteria' (≥five-times daily oral levodopa use, ≥two daily hours with 'Off' symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson's disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD - a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) - is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa-carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment. Clinical Trial Registration: NCT02611713 (ClinicalTrials.gov).
Databáze: MEDLINE